PMID- 26597250
OWN - NLM
STAT- MEDLINE
DCOM- 20160923
LR  - 20181113
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 13
DP  - 2015 Nov 24
TI  - Evidence-based support for the use of proton pump inhibitors in cancer therapy.
PG  - 368
LID - 10.1186/s12967-015-0735-2 [doi]
LID - 368
AB  - 'We can only cure what we can understand first', said Otto H. Warburg, the 1931 
      Nobel laureate for his discovery on tumor metabolism. Unfortunately, we still 
      don't know too much the mechanisms underlying of cancer development and 
      progression. One of the unsolved mystery includes the strategies that cancer 
      cells adopt to cope with an adverse microenvironment. However, we knew, from the 
      Warburg's discovery, that through their metabolism based on sugar fermentation, 
      cancer cells acidify their microenvironment and this progressive acidification 
      induces a selective pressure, leading to development of very malignant cells 
      entirely armed to survive in the hostile microenvironment generated by their own 
      metabolism. One of the most mechanism to survive to the acidic tumor 
      microenvironment are proton exchangers not allowing intracellular acidification 
      through a continuous elimination of H(+) either outside the cells or within the 
      internal vacuoles. This article wants to comment a translational process through 
      which from the preclinical demonstration that a class of proton pump inhibitors 
      (PPI) exploited worldwide for peptic ulcer treatment and gastroprotection are 
      indeed chemosensitizers as well, we have got to the clinical proof of concept 
      that PPI may well be included in new anti-cancer strategies, and with a solid 
      background and rationale.
FAU - Fais, Stefano
AU  - Fais S
AD  - Department of Therapeutic Research and Medicines Evaluation, National Institute 
      of Health (Istituto Superiore di Sanita), Viale Regina Elena 299, 00161, Rome, 
      Italy. stefano.fais@iss.it.
LA  - eng
PT  - Journal Article
DEP - 20151124
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Evidence-Based Medicine
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Proton Pump Inhibitors/*therapeutic use
PMC - PMC4657328
EDAT- 2015/11/26 06:00
MHDA- 2016/09/24 06:00
PMCR- 2015/11/24
CRDT- 2015/11/25 06:00
PHST- 2015/10/07 00:00 [received]
PHST- 2015/11/18 00:00 [accepted]
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
PHST- 2015/11/24 00:00 [pmc-release]
AID - 10.1186/s12967-015-0735-2 [pii]
AID - 735 [pii]
AID - 10.1186/s12967-015-0735-2 [doi]
PST - epublish
SO  - J Transl Med. 2015 Nov 24;13:368. doi: 10.1186/s12967-015-0735-2.